Open Access Open Access  Restricted Access Subscription Access

Signs, Symptoms, Mechanism of Action, Adverse Effects, Contraindications and Toxicity of Amoxicillin

Muralinath E., Yerikala Ramesh

Abstract


The U.S. Food and Drug Administration (FDA) has approved the widely used beta-lactam antibiotic medication amoxicillin for use in primary care settings. In order to combat antibiotic resistance, an additional amino group is added to penicillin to create amoxicillin, an aminopenicillin. This medication is intended to treat infections caused by susceptible isolates of specific bacteria, especially those that are beta-lactamase-negative. These infections include lower respiratory and urinary tract infections, acute bacterial sinusitis, ear, nose, and throat infections, Helicobacter pylori elimination, and skin and structure infections.

Compared to penicillin, amoxicillin is more efficient against a variety of gram-positive bacteria and provides additional protection against some gram-negative species. Amoxicillin is effective against Listeria monocytogenes and Enterococcus species, although it is also effective against Streptococcus species. Additionally, amoxicillin is effective against certain strains of Escherichia coli, Actinomyces, Clostridium, Salmonella, Shigella, and Corynebacteria, as well as Haemophilus influenzae. This exercise describes the signs, symptoms, administration, mechanism of action, contraindications, and profiles of adverse events associated with amoxicillin. This exercise gives medical professionals a thorough understanding of amoxicillin to improve their capacity to treat infectious infections in patients.


Full Text:

PDF

References


Shulman, S. T., Bisno, A. L., Clegg, H. W., Gerber, M. A., Kaplan, E. L., Lee, G., Martin, J. M., & Van Beneden, C. (2012). Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 55(10), e86–e102.

Matsumoto, H., Shiotani, A., & Graham, D. Y. (2019). Current and future treatment of Helicobacter pylori infections. Advances in Experimental Medicine and Biology, 1149, 211–225.

Chow, A. W., Benninger, M. S., Brook, I., Brozek, J. L., Goldstein, E. J., Hicks, L. A., Pankey, G. A., Seleznick, M., Volturo, G., Wald, E. R., & File, T. M. (2012). IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clinical Infectious Diseases, 54(8), e72–e112.

Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Ashok Kumar, K., Kramper, M., Orlandi, R. R., Palmer, J. N., Patel, Z. M., Peters, A., Walsh, S. A., & Corrigan, M. D. (2015). Clinical practice guideline (update): Adult sinusitis. Otolaryngology–Head and Neck Surgery, 152(2 Suppl.), S1–S39.

Sartelli, M., Guirao, X., Hardcastle, T. C., Kluger, Y., Boermeester, M. A., Raşa, K., Ansaloni, L., Coccolini, F., Montravers, P., Abu-Zidan, F. M., Bartoletti, M., Bassetti, M., Ben-Ishay, O., Biffl, W. L., Chiara, O., Chiarugi, M., Coimbra, R., De Rosa, F. G., De Simone, B., ... Catena, F. (2018). 2018 WSES/SIS-E consensus conference: Recommendations for the management of skin and soft-tissue infections. World Journal of Emergency Surgery, 13, Article 58.

Tan, C. W., & Chlebicki, M. P. (2016). Urinary tract infections in adults. Singapore Medical Journal, 57(9), 485–490.

Hendricks, K. A., Wright, M. E., Shadomy, S. V., Bradley, J. S., Morrow, M. G., Pavia, A. T., Rubinstein, E., Holty, J. E., Messonnier, N. E., Smith, T. L., Pesik, N., Treadwell, T. A., & Bower, W. A. (2014). Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerging Infectious Diseases, 20(2).

Chomel, B. (2015). Lyme disease. Revue Scientifique et Technique, 34(2), 569–576.

Wilson, W., Taubert, K. A., Gewitz, M., Lockhart, P. B., Baddour, L. M., Levison, M., Bolger, A., Cabell, C. H., Takahashi, M., Baltimore, R. S., Newburger, J. W., Strom, B. L., Tani, L. Y., Gerber, M., Bonow, R. O., Pallasch, T., Shulman, S. T., Rowley, A. H., Burns, J. C., ... Durack, D. T. (2007). Prevention of infective endocarditis: Guidelines from the American Heart Association. Circulation, 116(15), 1736–1754.

Germack, M., Sedgley, C. M., Sabbah, W., & Whitten, B. (2017). Antibiotic use in 2016 by members of the American Association of Endodontists: Report of a national survey. Journal of Endodontics, 43(10), 1615–1622.

Bonifaz, A., Tirado-Sánchez, A., Calderón, L., Montes de Oca, G., Torres-Camacho, P., & Ponce, R. M. (2017). Treatment of cutaneous actinomycosis with amoxicillin/clavulanic acid. Journal of Dermatological Treatment, 28(1), 59–64.

Bernatová, S., Samek, O., Pilát, Z., Serý, M., Ježek, J., Jákl, P., Šiler, M., Krzyžánek, V., Zemánek, P., Holá, V., Dvořáčková, M., & Růžička, F. (2013). Following the mechanisms of bacteriostatic versus bactericidal action using Raman spectroscopy. Molecules, 18(11), 13188–13199.

Weber, D. J., Tolkoff-Rubin, N. E., & Rubin, R. H. (1984). Amoxicillin and potassium clavulanate: An antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects. Pharmacotherapy, 4(3), 122–136.

Szultka, M., Krzemiński, R., Jackowski, M., & Buszewski, B. (2014). Identification of in vitro metabolites of amoxicillin in human liver microsomes by LC-ESI/MS. Chromatographia, 77(15), 1027–1035.

Peng, J., Ladumor, M. K., & Unadkat, J. D. (2021). Prediction of pregnancy-induced changes in secretory and total renal clearance of drugs transported by organic anion transporters. Drug Metabolism and Disposition, 49(10), 929–937.

Reed, M. D. (2000). Optimal antibiotic dosing: The pharmacokinetic-pharmacodynamic interface. Postgraduate Medicine, 108(7 Suppl.), 17–24.

Maguigan, K. L., Al-Shaer, M. H., & Peloquin, C. A. (2021). Beta-lactam dosing in critically ill patients with Gram-negative bacterial infections: A PK/PD approach. Antibiotics, 10(10).

Damkier, P., Brønniche, L. M. S., Korch-Frandsen, J. F. B., & Broe, A. (2019). In utero exposure to antibiotics and risk of congenital malformations: A population-based study. American Journal of Obstetrics and Gynecology, 221(6), 648.e1–648.e15.

National Library of Medicine. (2026, June 15). Amoxicillin. In Drugs and Lactation Database (LactMed®). National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/

Vodovar, D., Thomas, L., Mongardon, N., Lepeule, R., Lebrun-Vignes, B., Biour, M., Netzer, F., Haouache, H., Le Beller, C., & Dhonneur, G. (2018). Dramatic increase of amoxicillin-induced crystal nephropathy found in a cohort study of French pharmacovigilance centers. Antimicrobial Agents and Chemotherapy, 62(3).


Refbacks

  • There are currently no refbacks.